August 29, 2017 / 11:06 PM / a year ago

FDA approves Medicines Co's urinary tract infection drug

(Reuters) - The U.S. Food and Drug Administration said on Tuesday it has approved Medicines Co’s antibacterial drug for patients with complicated urinary tract infections (cUTI).

A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. REUTERS/Jason Reed

The drug, Vabomere, was approved to treat adults with cUTI, including pyelonephritis, a potentially life-threatening infection caused by bacteria traveling from the bladder into one or both of the kidneys.

The FDA said it was granting approval of Vabomere to Rempex Pharmaceuticals, a unit of Medicines Co.

Vabomere contains an antibacterial and an inhibitor which deters certain resistance mechanisms used by bacteria.

Shares of Medicines Co were up over 4 percent at $40.46 in after-hours trading on Tuesday.

Reporting by Manas Mishra in Bengaluru

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below